The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points

@article{Lai2007TheNH,
  title={The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points},
  author={Ching-lung Lai and Man‐Fung Yuen},
  journal={Annals of Internal Medicine},
  year={2007},
  volume={147},
  pages={58-61}
}
  • C. Lai, M. Yuen
  • Published 3 July 2007
  • Medicine
  • Annals of Internal Medicine
Approximately 350 to 400 million people worldwide have chronic hepatitis B virus (HBV) infection, with roughly 1.25 million cases in the United States and 180000 in Britain. More than 70% of all people with chronic HBV infection are Asian. Although white persons in the U.S. and British populations are usually infected in adolescence or adulthood (by means of sexual contact or sharing of intravenous needles), nearly every Asian person with this infection (whether born in or outside Asia… Expand
Hepatitis B: diagnosis and treatment.
Although an estimated 1 million persons in the United States are chronically infected with hepatitis B virus, the prevalence of hepatitis B has declined since the implementation of a nationalExpand
Screening for Hepatitis B Virus Infection in Adolescents and Adults: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation
TLDR
The purpose of this report is to review the current evidence on screening for HBV infection in asymptomatic adolescents and adults, excluding pregnant women, and to include additional key questions on the benefits and harms of antiviral treatment and the association between improvements in intermediate outcomes after antiviral therapy and subsequent clinical outcomes. Expand
Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B
TLDR
In patients with chronic hepatitis B (CHB) infection, it is important to monitor the natural history, assess treatment response, and predict the risk of liver-related complications, and ongoing studies are required to demonstrate the sustainability of HBsAg suppression by these novel agents. Expand
Characteristics and course of chronic hepatitis B e antigen-negative infection
TLDR
Among HBV carriers with negative HBe antigen, inactive HBs-Ag carriers are predominant andHBV-DNA gradually decreases in the first few years after diagnosis, especially if glutamic pyruvic transaminase (GPT) is normal and HBV- DNA levels are low at diagnosis. Expand
Can long term therapy with oral nucleos(t)ide analogs influence the prognosis of chronic hepatitis B‐related complications?
  • M. Ooi, N. Teoh
  • Medicine
  • Journal of gastroenterology and hepatology
  • 2012
TLDR
It appears that the progression to cirrhosis and HCC in these patients is associated with persistently high serum HBV DNA levels over time, and complete suppression, or elimination of HBV is now eminently feasible and well-tolerated, and should be the key management goal in the treatment of CHB. Expand
When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection?
TLDR
HBeAg seroconversion seems an appropriate treatment end point in most patients, and the presence of risk factors for progressive liver disease, such as older age, HBeAg positivity, high serum HBV DNA levels, and co-infection with hepatitis C or D virus, can be used to identify patients with normal ALT levels who warrant further evaluation and treatment. Expand
A PRACTICAL APPROACH TO CHRONIC HEPATITIS B TREATMENT
TLDR
The indications for treatment, available drugs, and identify drug resistance or intolerance and primary treatment failure in chronic hepatitis B are discussed and Appropriate early treatment decreases mortality and morbidity rate caused by liver disease. Expand
Chronic hepatitis B--new goals, new treatment.
TLDR
The criteria and end points for the treatment of chronic HBV infection should be reevaluated in light of three important recent findings. Expand
Treatment of chronic hepatitis B: Evolution over two decades
  • M. Yuen, C. Lai
  • Medicine
  • Journal of gastroenterology and hepatology
  • 2011
TLDR
With these current, potent antiviral agents associated with very low rates of resistance, long‐term HBV DNA suppression and possibly even reversal of cirrhosis can now be achieved in a proportion of patients. Expand
Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options
TLDR
There is no established benefit of treatment of children in the immune tolerant phase, and there is a very high risk of development of drug resistance, so a conservative approach is warranted. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Management of hepatitis B: 2000--summary of a workshop.
TLDR
This review provides a summary of a 3-day research workshop on September 8 ‐10, 2000 entitled “Management of Hepatitis B: 2000” and concluding recommendations on management of chronic hepatitis B. Expand
Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.
TLDR
Over a 30-year period, chronic HBV carrier blood donors from Northern Italy did not develop clinically significant liver disease, hepatocellular cancer, or other liver-related morbidity or mortality at a higher rate than uninfected controls. Expand
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
TLDR
In patients with chronic hepatitis B infection, the clearance of HBeAg after treatment with interferon alfa is associated with improved clinical outcomes, and overall survival and survival without clinical complications were significantly longer in patients who were seronegative for H beAg after therapy withInterferonAlfa. Expand
Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications
TLDR
Prolonged low level viraemia causing insidious and continual liver damage, as reflected by ALT levels of 0.5–2× ULN, is the most likely pathway for the development of complications in Asian CHB patients. Expand
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.
  • E. Keeffe, D. Dieterich, +5 authors T. Wright
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2006
TLDR
A treatment algorithm for CHB previously developed and published by a panel of United States hepatologists was revised based on new developments in the understanding of CHB, the availability of more sensitive molecular diagnostic testing, the addition of new treatments, and better understanding of the advantages and disadvantages of approved therapies. Expand
The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
TLDR
In addition to age factor, the extent, severity, duration, frequency and etiology of the hepatic lobular alterations are important factors for the development of cirrhosis in patients with chronic type B hepatitis. Expand
Lamivudine for patients with chronic hepatitis B and advanced liver disease.
TLDR
Continuous treatment with lamivudine delays clinical progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis by significantly reducing the incidence of hepatic decompensation and the risk of hepatocellular carcinoma. Expand
Predicting survival in hepatitis B
TLDR
Alanine aminotransferase (ALT) level alone is not an appropriate indication for therapy in chronic hepatitis B infection, and other criteria in addition to ALT must be used to determine eligibility for therapy, and new predictors of outcome have been identified. Expand
Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update *
TLDR
To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings were discussed and debated. Expand
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection.
TLDR
SerumHBV DNA levels decreased significantly in patients with HBeAg loss, but there was no threshold HBV DNA level associated with H beAg clearance, and it is not possible to define a single cutoff HBVDNA value for differentiating inactive carriers from patients withHBeAg-negative chronic hepatitis. Expand
...
1
2
3
4
...